What is KEYNOTE 240 Outcome in HCC

What is KEYNOTE 240 Outcome in HCC

obr

1 year
109 Views
Share Report
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:

Daneng Li, MD, Assistant Clinical Professor, Department of Medical Oncology & Therapeutics Research, Liver Program Disease Team Lead, City of Hope, explains the outcomes from KEYNOTe 240 trial comparing pembrolizumab versus placebo in 1st line hepatocellular carcinoma (HCC) patients.

Up Next Autoplay